Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma

Kitajima, Masaki; Hamasaki, Koji; Wakata, Kouki; Tobinaga, Syuichi; Sumida, Yorihisa; Hidaka, Shigekazu; Yasutake, Toru; Miyazaki, Takuro; Matsumoto, Keitaro; Yamasaki, Takuya; Sawai, Terumitsu; Hamamoto, Ryuji; Nanashima, Atsushi; Nagayasu, Takeshi

doi:10.21873/anticanres.12419

Cited by 14 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, a number of clinical laboratory tests (including the detection of tumor markers in the serum) have been developed to predict the prognosis of patients with ESCC. These tests have been evaluated in numerous validation cohorts, and are able to assist in the application of personalized chemotherapy programs (34,35). In the present study, the OS of patients with stage III and IV ESCC was predicted using the five-gene signature, tough a larger sample population may have been more beneficial to validate the prognostic value of the five-gene signature in patients with stage III and IV ESCC; further studies will be conducted to demonstrate whether the five-gene signature can help to determine the benefit of adjuvant chemotherapy for patients with stage III and IV ESCC.…”

Section: Discussionmentioning

confidence: 99%

A five‑gene signature to predict the overall survival time of patients with esophageal squamous cell carcinoma

Yan

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) is one of the six most commonly diagnosed tumor types in the Chinese population. Gene expression profiles help to predict the prognosis of patients with ESCC. Disease recurrence as the survival endpoint has been analyzed in the majority of previous studies; therefore, the aim of the present study was to construct a robust gene signature in order to determine the overall survival (OS) of patients with ESCC. The gene expression and clinical data of patients with ESCC were downloaded from The Cancer Genome Atlas (TCGA) database. Of the selected data (172 samples from surviving patients), 72 samples were randomly selected as modeling data, and verification was conducted using the entire dataset. Data from the Gene Expression Omnibus was analyzed simultaneously, and a venn diagram was constructed to determine the intersection between these two sets of results; a total of 97 genes were found to be associated with OS. Kyoto Encyclopedia of Genes and Genomes analysis demonstrated that these genes were primarily associated with specific pathways (Homo sapiens), including DNA replication, protein processing in endoplasmic reticulum and influenza A. A five-gene signature was identified with a robust likelihood-based survival modeling approach. Using regression coefficient modeling, a prognostic model consisting of the C-X-C motif chemokine ligand 8, DNA damage inducible transcript 3, RAB27A, member RAS oncogene family, replication factor C subunit 2 and elongation factor for RNA polymerase II 2 genes was constructed and validated. Based on these results, patients were subdivided into high and low-risk groups. Compared with the high-risk group, the OS time of patients in the low-risk group was significantly increased. Furthermore, it was determined that the five genes were all differentially expressed in ESCC tissues compared with normal tissues, indicating the potential role of these genes in ESCC initiation and progression. In another independent cohort, this five-gene signature was further confirmed and was considered as an independent prognostic biomarker for OS prediction in patients with ESCC. In conclusion, the OS of patients with ESCC may be predicted using this five-gene signature, which may be useful in identifying patients with high-risk ESCC.

show abstract

Section: Discussionmentioning

confidence: 99%

A five‑gene signature to predict the overall survival time of patients with esophageal squamous cell carcinoma

Yan

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…After screening the article according to flow chart in Figure 1 , 12 studies were selected [ 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ]. A total of 2094 patients were included from these studies.…”

Section: Resultsmentioning

confidence: 99%

“…Studies as duplicates, animal studies, cellular studies, or letters to the editor or reviews were excluded. After viewing the titles and abstracts, the full texts of 34 studies were retrieved and 12 studies [ 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ] were included in the analysis because they had the hazard ratio available for survivals ( Table 1 and Table 2 ) as summarized in the flow chart of Figure 1 .…”

Section: Methodsmentioning

confidence: 99%

p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Importance: The protein p53 is an unequivocal tumor suppressor that is altered in half of all cancers. The immune system produces systemic p53 autoantibodies (p53 Abs) in many cancer patients. Objective: This systemic review and meta-analysis focuses on the prognostic value of p53 Abs expressed in the serum of patients with solid tumors. Data Sources: All the clinical investigations were searched on PubMed from the first study dated 1993 until May 2021 (date of submission of the manuscript). Study Selection: Studies were included that met the following criteria: 1) participants with cancer; 2) outcome results expressed in relation to the presence of a p53 antibody; 3) a primary outcome (disease-free survival, overall survival or progression-free survival) expressed as hazard ratio (HR). The following exclusion criteria were used: 1) insufficient data available to evaluate outcomes; 2) animal studies; 3) studies with less than 10 participants. As a result, 12 studies were included in the analysis. Data Extraction and Synthesis: PRISMA guidelines were used for abstracting and assessing data quality and validity by three independent observers. The summary estimates were generated using a fixed-effect model (Mantel–Haenszel method) or a random-effect model (DerSimonian–Laird method), depending on the absence or presence of heterogeneity (I2). Main Outcome(s) and Measure(s): The primary study outcome was to determine the prognostic value of p53 Abs from a large population of patients with solid tumors, as determined before data collection. Results: In total, 12 clinical studies involving 2094 patients were included in the meta-analysis, and it was determined that p53 Abs expression in the serum significantly correlated with poorer survival outcomes of cancer patients (95% CI 1.48 [1.24, 1.77]; p < 0.00001). Conclusions and Relevance: This is the first meta-analysis proving the diagnostic utility of p53-Abs for cancer patients in predicting poorer outcomes. The serum-p53 value (s-p53-value) may be useful for future theranostics.

show abstract

“…Of these cases, 259,000 were ESCC, making it the fifth most prevalent malignant tumor ( 6 ). Tumor recurrence and metastasis are leading causes of mortality in patients with ESCC ( 7 ). It has previously been reported that immunosuppression is associated with tumor recurrence and metastasis ( 8 , 9 ), however the underlying mechanism remains to be elucidated.…”

Section: Introductionmentioning

confidence: 99%

Propofol improves the function of natural killer cells from the peripheral blood of patients with esophageal squamous cell carcinoma

et al. 2018

View full text Add to dashboard Cite

Postoperative immunosuppression is associated with the recurrence and metastasis of esophageal squamous cell carcinoma (ESCC). Propofol is a commonly used intravenous anesthetic and has been reported to be associated with immunosuppression; however, little is known about its effect on innate immune cells during the postoperative period in patients with ESCC. The aim of the present study was to investigate the effects of propofol on the phenotype and cytotoxicity of natural killer (NK) cells derived from the peripheral blood of patients with ESCC. The percentage, phenotype and function of NK cells were compared between patients with ESCC and healthy volunteers using flow cytometry. NK cells were negatively sorted using magnetic beads and cocultured with propofol to assess changes in phenotype and function. The results revealed that the percentage of NK cells was significantly increased in the peripheral blood of patients with ESCC, while their activity and cytotoxicity were impaired. NK cells were successfully separated from peripheral blood in vitro and it was demonstrated that propofol enhanced their activity by influencing the expression of activating or inhibitory receptors. Furthermore, propofol was able to increase the cytotoxicity of NK cells from the peripheral blood of patients with ESCC. These results suggest that propofol is able to improve the function of NK cells in patients with ESCC and may therefore be an appropriate anesthetic for ESCC surgery.

show abstract

Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma

Abstract: The diagnostic rate with S-p53Ab was better than that with SCC-Ag and CEA in patients with early-stage ESCC. Combined detection of S-p53Ab and SCC-Ag can markedly improve diagnostic sensitivity and may permit more accurate stratification of patients with ESCC.

Cited by 14 publications

References 0 publications

A five‑gene signature to predict the overall survival time of patients with esophageal squamous cell carcinoma

A five‑gene signature to predict the overall survival time of patients with esophageal squamous cell carcinoma

p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis

Propofol improves the function of natural killer cells from the peripheral blood of patients with esophageal squamous cell carcinoma

Contact Info

Product

Resources

About